Listing timing unconfirmed
Last verified 11 Oct 2026The previously expected date of 28 Sept 2026 has passed. Trading has not been confirmed.
- Indicative valuation
- $53.7M to $53.7MBasic equity value after the offering
- Price range
- $5.00 to $5.00Per share · USD
- Offering size
- $15MBase offering, before overallotment
- Previously expected
- 28 Sept 2026Listing timing unconfirmed
Company overview
Encore Medical websiteThe company’s septal occlusion products are small devices delivered through a catheter inserted into a major blood vessel. They are intended to permanently repair certain cardiac defects.
- Company country
- United States
Offering details
USD · Base offering, before overallotment
- Exchange
- NYSE American
- Ticker
- EMI
- Shares offered
- 3,000,000
- Shares after offering
- 10,743,425
- New shares
- 3,000,000
- Existing shares sold
- 0
- Gross proceeds to company
- $15M to $15M
- Gross proceeds to shareholders
- $0 to $0
IPO timeline
- Registration filed
- Proposed terms published
- Previously expected first trading day · Announced date